These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14525540)

  • 21. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients.
    Becher F; Pruvost AG; Schlemmer DD; Créminon CA; Goujard CM; Delfraissy JF; Benech HC; Grassi JJ
    AIDS; 2003 Mar; 17(4):555-61. PubMed ID: 12598776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
    AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
    García-Lerma JG; MacInnes H; Bennett D; Reid P; Nidtha S; Weinstock H; Kaplan JE; Heneine W
    J Virol; 2003 May; 77(10):5685-93. PubMed ID: 12719561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
    Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
    Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance-associated mutations after initial antiretroviral treatment failure in a large cohort of patients infected with HIV-1 subtype CRF01_AE.
    Praparattanapan J; Kotarathitithum W; Chaiwarith R; Nuntachit N; Sirisanthana T; Supparatpinyo K
    Curr HIV Res; 2012 Dec; 10(8):647-52. PubMed ID: 23061604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
    Winston A; McAllister J; Amin J; Cooper DA; Carr A
    HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.
    Recordon-Pinson P; Papuchon J; Reigadas S; Deshpande A; Fleury H
    PLoS One; 2012; 7(5):e36549. PubMed ID: 22615779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.
    Kuritzkes DR; Bassett RL; Hazelwood JD; Barrett H; Rhodes RA; Young RK; Johnson VA;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):600-3. PubMed ID: 15097303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G; Romano L; Catucci M; Riccio ML; De Milito A; Gonnelli A; Rubino M; Valensin PE; Zazzi M
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):274-82. PubMed ID: 10385016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.
    White KL; Margot NA; Ly JK; Chen JM; Ray AS; Pavelko M; Wang R; McDermott M; Swaminathan S; Miller MD
    AIDS; 2005 Nov; 19(16):1751-60. PubMed ID: 16227782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.
    Middleton T; Smith D; Larder B; Law M; Birch C
    HIV Clin Trials; 2001; 2(6):445-52. PubMed ID: 11742431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
    Coakley EP; Gillis JM; Hammer SM
    AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.
    McGrath CJ; Njoroge J; John-Stewart GC; Kohler PK; Benki-Nugent SF; Thiga JW; Etyang A; Chung MH
    J Neurovirol; 2012 Jun; 18(3):200-4. PubMed ID: 22528481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.
    Van Dyke RB; Wang L; Williams PL;
    J Infect Dis; 2008 Dec; 198(11):1599-608. PubMed ID: 19000014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
    Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
    Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.